Clinical Trial

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Study acronym: SEQUOIA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2017-11-07; most recent amendment 2026-02-17.
Status change: Recruiting → Active, Not Recruiting 2022-06-24
Status change: Active, Not Recruiting → Recruiting 2019-10-16
Status change: Recruiting → Active, Not Recruiting 2019-06-21
Trial Details
NCT Number NCT03336333
Lead Sponsor BeiGene
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 590 participants
Start Date 2017-10-31
Primary Completion 2021-05-07 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-09